Fig. 2From: Randomized phase II study of SOX+B-mab versus SOX+C-mab in patients with previously untreated recurrent advanced colorectal cancer with wild-type KRAS (MCSGO-1107 study)Kaplan-Meier curves for overall survival and progression-free survival for all patients (a) and patients with left-sided colorectal cancer (b). Solid black line: SOX+B-mab, dotted black line: SOX+C-mab. * indicates < 0.05Back to article page